Welcome to our dedicated page for Mindset Pharma news (Ticker: MSSTF), a resource for investors and traders seeking the latest updates and insights on Mindset Pharma stock.
Mindset Pharma Inc. is a drug discovery company that focuses on developing novel psychedelic and non-psychedelic medications to address neuropsychiatric and neurological disorders with unmet medical needs. The company recently entered into a definitive arrangement agreement with Otsuka Pharmaceutical Co., Ltd., signaling a significant acquisition worth approximately CAD $80 million. Mindset's innovative compounds and synthesis processes aim to revolutionize the treatment of psychiatric disorders, contributing to patient care on a global scale.
The Transaction, expected to close in October 2023, marks a strategic move by Otsuka to strengthen its presence in the psychiatry and neurology therapeutic areas. Mindset's shareholders will benefit from the all-cash acquisition, demonstrating a premium value of $0.75 per share. With a focus on maximizing the value of its assets and IP portfolio, Mindset's collaboration with Otsuka is poised to lead to groundbreaking advancements in patient treatment.
In pursuit of its mission to develop next-generation pharmaceutical assets, Mindset is dedicated to creating optimized and patentable psychedelic medicines, leveraging the therapeutic potential of psychedelic drugs. Through proprietary compounds, novel families of psychedelic compounds, and innovative synthesis processes, the company is at the forefront of advancing treatment options for neurological and psychiatric conditions.
Mindset Pharma Inc. (OTCQB: MSSTF), a leader in developing next-generation psychedelic medicines, will participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021. CEO James Lanthier will join the Future of Mental Healthcare panel at 2:30 p.m. ET, with his corporate presentation available on-demand from 7:00 a.m. ET. Mindset focuses on drug discovery to address neurological and psychiatric disorders, creating optimized psychedelic compounds and innovating psilocybin synthesis. More details can be found on their website.
Mindset Pharma Inc. (OTCQB: MSSTF) presented preclinical data on its psilocybin analog, MSP-1014, at the Society for Neuroscience meeting. The presentation highlighted the pharmacokinetic and pharmacodynamic properties linked to the 5-HT2A receptor, showcasing the drug's potential for treatment-resistant depression and end-of-life cancer angst. The data strengthens the company’s research credibility within the scientific community. MSP-1014 aims to address significant unmet medical needs in neurological disorders, marking a crucial step towards human clinical trials.
Mindset Pharma Inc. (OTCQB: MSSTF) announced significant progress in its drug development pipeline, focusing on next-generation psychedelic medicines aimed at mental health disorders. The company has moved its lead candidate, MSP-1014, a psilocybin-based compound, into IND-enabling studies, targeting treatment-resistant depression and end-of-life cancer angst. It has expanded its patent portfolio with eight provisional applications and provided preclinical evidence of enhanced safety and efficacy across four drug families. Fiscal year-end cash was approximately $6.6 million, indicating a solid capital position for growth.
Mindset Pharma (OTCQB: MSSTF) announced its participation in Microdose’s Wonderland: Miami on November 8-9, 2021. The company's CEO, James Lanthier, and CSO, Joseph Araujo, will present Beyond Psilocybin: New Frontiers in Psychedelic Drug Design at 12:45 p.m. ET on November 8. Mindset Pharma focuses on developing next-generation psychedelic medicines addressing neurological and psychiatric disorders. For more details, visit www.mindsetpharma.com.
Mindset Pharma Inc. (OTCQB: MSSTF) has advanced its psychedelic medicine research through its COPE program with InterVivo Solutions. This initiative established standard pharmacokinetic data and protocols for LSD, psilocybin, and 5-MeO-DMT. CEO James Lanthier highlighted the potential market opportunity in providing benchmarking data against first-generation compounds. The program aims to create a comprehensive psychedelics benchmark reference data set, aiding the development of next-generation drugs for neurological and psychiatric disorders.
Mindset Pharma Inc. (OTCQB: MSSTF) announced that its CEO, James Lanthier, will participate in the KCSA Psychedelics Investor Conference on October 13-14, 2021. Mr. Lanthier will present live on October 14 at 10:00 a.m. ET. Mindset Pharma focuses on developing next-generation psychedelic medicines for neurological and psychiatric disorders. The conference aims to facilitate direct interaction between publicly-traded companies and investors, enhancing engagement in an innovative format.
Mindset Pharma (OTCQB: MSSTF) announced positive preclinical results for its compounds MSP-4019 and MSP-4020, demonstrating efficacy and an improved safety profile compared to 5-MeO-DMT. Utilizing conjugate amplification technology, these next-generation psychedelic medicines aim to address mental health disorders effectively. The compounds showed no signs of 5-HT syndrome, a concern with earlier drugs. The company plans to advance these candidates into clinical trials following further validation.
Mindset Pharma (OTCQB: MSSTF) has been included in the AdvisorShares Psychedelics ETF (PSIL), which focuses on investments in the burgeoning psychedelic drugs sector. This actively managed ETF primarily invests in companies that generate significant revenue from psychedelic drugs. CEO James Lanthier expressed enthusiasm over this inclusion, viewing it as a positive advancement for both the company and the broader industry. The announcement signifies growing recognition of Mindset as a leader in the psychedelic medicine market, particularly for neurological and psychiatric disorders.
Mindset Pharma Inc. (OTCQB: MSSTF) announced preclinical proof-of-concept data showcasing its candidate MSP-4018, demonstrating superior efficacy and safety compared to 5-MeO-DMT. The company is optimistic about advancing to human clinical trials due to this promising data. Observations indicated that MSP-4018 maintained locomotor activity and rearing behavior across various doses, contrasting the declines noted in 5-MeO-DMT. Mindset's proprietary Family 4 compounds highlight a commitment to developing optimized psychedelic medicines for neurological and psychiatric disorders.
Mindset Pharma has reported promising results for its lead candidate, MSP-1014, in a drug discrimination assay, demonstrating effects comparable to psilocybin. The study identified an effective dosage of 0.6 mg/kg with no adverse effects at doses up to 2 mg/kg. This further confirms MSP-1014 as a viable second-generation psychedelic drug. The company aims to continue preclinical studies and prepare for human clinical trials. The results underscore Mindset's commitment to developing next-generation psychedelic medicines for neurological and psychiatric disorders.
FAQ
What is the market cap of Mindset Pharma (MSSTF)?
What is Mindset Pharma Inc. focused on?
What recent agreement did Mindset Pharma Inc. enter into?
How will the acquisition benefit Mindset Pharma Inc.'s shareholders?
What is the focus of Mindset Pharma Inc.'s drug development programs?
What is the expected timeline for the completion of the Transaction between Mindset Pharma Inc. and Otsuka Pharmaceutical Co., Ltd.?
How does the collaboration between Mindset Pharma Inc. and Otsuka Pharmaceutical Co., Ltd. contribute to patient care?
What sets Mindset Pharma Inc. apart in the pharmaceutical industry?
